Circio presents circVec circular RNA in vivo expression proof-of-concept data at ESGCT 2024 annual meeting

24 Oct 2024 12:00 CEST

· Circio selected to present its circVec circular RNA expression platform at the
European Society of Cell and Gene Therapy (ESGCT) annual meeting in Rome 22-25
October; a prestigious and widely attended international gene therapy conference
· Circio presented new circVec protein expression data showing statistically
significant advantage vs. conventional mRNA-based vector expression both in
vitro and in vivo
· The circVec 2.1 generation shows 15x increase in protein expression in vivo,
and has the potential to substantially improve on the performance of current
gold-standard gene therapy approaches

Oslo, Norway 24 October 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing next generation circular RNA vector technology for gene
therapy, today announces the publication of new, strong and statistically
significant circVec circular RNA in vivo expression proof-of-concept data,
presented both in the form of a poster and oral presentation by CTO, Dr. Thomas
B Hansen, at the European Society of Cell and Gene Therapy (ESGCT) annual
meeting 2024.

"Circio continues to build momentum with the unique and powerful circVec
platform. We selected the prestigious ESGCT meeting to present our latest
results as it provided a great opportunity to showcase our technology to a broad
life science industry and academic audience," said Dr. Thomas B. Hansen, CTO of
Circio. "circVec significantly outperforms mRNA-based expression both in vitro
and in vivo and has the potential to offer substantial enhancement over current
gold-standard gene therapy approaches."

In the ESGCT presentation, Circio showed the evolution and improvements of the
circVec platform from the initial circVec 1.0 design to the current generation
2.1. Long-term in vivo experiments have now demonstrated that circVec 2.1
robustly outperforms classical mRNA-based expression over time, offering
enhanced durability that reaches up to 15-fold higher reporter signals in mouse
models. Additionally, a machine-learning approach to codon optimization has
generated a novel circVec 2.2 design, delivering a further 2-4-fold increase in
protein yield.

Circio is currently testing the performance of circVec 2.1 and 2.2 in both viral
and DNA vector systems in multiple tissues and disease settings in vivo. These
data will guide future development and partnering strategy for the circVec
platform.

The ESGCT slides and poster are attached hereto, and will also be made available
on www.circio.com

Title of presentation and poster:

Optimization of in vitro and in vivo performance of circVec, a vector-based
circular RNA expression platform for enhanced gene therapy

Presenter: Dr. Thomas B Hansen, CTO

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Neil Hunter, Hunter PR
Phone: +44 7821 255568
Email: neiljameshunter@gmail.com

About Circio

Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA gene
therapies and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) expression platform for
genetic medicine. The proprietary circVec technology is based on a modular
genetic cassette design for efficient biogenesis of multifunctional circRNA from
DNA and viral vectors, which can be deployed in multiple disease settings,
including cell and gene -therapy and chronic diseases. The circVec platform has
demonstrated enhanced and more durable protein expression vs. classic mRNA
vector systems and has the potential to become the new gold-standard for DNA and
virus-based therapeutics in the future. The circRNA R&D activities are being
conducted by the wholly owned subsidiary Circio AB based at the Karolinska
Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.

More information:
Access the news on Oslo Bors NewsWeb site

630300_Circio_ESGCT_2024_poster.pdf
630300_Circio_ESGCT_2024_presentation.pdf